Prof. Dr. Simon Schäfer leads the Schäfer Lab at the Technische Universität München , focusing on engineering advanced organoid systems to study human brain development, disease modeling, and repair mechanisms. His work bridges stem cell biology, gene editing, and bioengineering to develop personalized therapies for brain disorders. Stem Cell & Organoid Technology Neurodevelopmental Mechanisms Neurodegenerative Disease Models Gene Editing & Neuroimmune Interactions Translational Neuroscience Recent research emphasizes brain organoid development, microglia phenotypes, and neurodevelopmental timing anomalies in autism. His team’s work also explores zika virus interactions with glioblastoma stem cells and neuronal plasticity in psychiatric disorders. Scientific awards and funding include support from the Deutsche Forschungsgemeinschaft (DFG), Brain & Behavior Research Foundation (BBRF), and Munich Cluster for Systems Neurology (SyNergy). Collaborations span institutions like the TUM Center for Organoid Systems. Advises 6 students (2 PhD, 1 MSc, 3 associated) Labs include Schäfer Lab, COS@TranslaTUM Contact: simon.schafer@tum.de
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Jens S. Andersen is a Professor in the Department of Biochemistry and Molecular Biology at the University of Southern Denmark, where he leads research in Biomedical Mass Spectrometry and Systems Biology. His work is centered on the development and application of quantitative mass spectrometry and microscopy-based proteomics to study human cell biology, particularly the structure and function of organelles such as centrosomes, cilia, autophagosomes, and mitochondria. His research focuses on determining the protein composition and dynamic properties of cellular organelles, the roles of specific protein groups, and their contributions to biological processes and diseases. He investigates cell signaling mediated by post-translational modifications, especially within the DNA damage response, autophagy, and immune systems. His lab, the Jens S. Andersen Lab, is part of the Research Section of Biomedical Mass Spectrometry. The analysis of his recent publications reveals a strong interdisciplinary trend combining proteomics, structural biology, and cell signaling. His work spans cilia biology, RNA metabolism, DNA repair, and cancer mechanisms, with frequent use of advanced techniques like mass spectrometry, CRISPR, and live-cell imaging. The integration of systems biology approaches is evident across his research outputs. Professor, Department of Biochemistry and Molecular Biology, University of Southern Denmark Head of Research, Biomedical Mass Spectrometry and Systems Biology Principal Investigator, Jens S. Andersen Lab ORCID: 0000-0002-6091-140X While no specific scientific awards are mentioned in the provided texts, his extensive publication record in high-impact journals such as Science , Nature Communications , Molecular Cell , and EMBO Journal reflects significant scholarly contributions. He has supervised research projects and collaborated widely across Europe, though specific names of students are not listed. His research is supported by multiple ongoing projects, reflecting sustained funding and academic leadership. The Jens S. Andersen Lab operates at the intersection of proteomics and cell biology, contributing to fundamental understanding of organelle dynamics and disease mechanisms. The lab's work is highly collaborative, involving partnerships with groups in structural biology, RNA research, and cancer biology.
Dr. Thomas A. Hughes is an Associate Professor of Cancer Biology at the University of Leeds and Professor of Biosciences at York St John University. As a Group Leader at the Leeds Institute of Medical Research, he focuses on gene regulation, tumour microenvironment, and nanomedicine approaches to improve cancer outcomes. Specializes in breast cancer, colorectal cancer, and rare diseases Develops therapeutic strategies using microRNAs and biomarkers Collaborates with clinicians, engineers, and chemists for translational research His research integrates molecular pathology with clinical data through partnerships with Leeds NHS Trusts, aiming to identify novel biomarkers and targets for therapy. Recent work emphasizes cholesterol metabolism, oxysterol signaling, and nanomedicine-based drug delivery systems. Key contributions include: Over 80 peer-reviewed publications in cancer biology and molecular therapeutics Leadership in MSc programs in Molecular Medicine and Cancer Biology and Therapy Extensive experience in grant review, editorial work, and doctoral supervision Scientific awards include Fellowship of the Higher Education Academy. His lab has mentored 26 doctoral students and numerous alumni in academia, clinical practice, and industry.
Ramesh Shanmughom Pillai is a Full Professor at the Department of Molecular Biology, University of Geneva, Switzerland. He holds additional roles as a Visiting Professor at the University of Kumamoto, Japan, and has been a Group Leader at EMBL Grenoble and a postdoctoral fellow at the Friedrich Miescher Institute. His research focuses on RNA modifications, epigenetics, and piRNA pathways in germline biology. Pillai has received prestigious awards including the ERC Consolidator Grant and The RNA Society Scaringe Award. Education: BSc Botany (University of Kerala, India) MSc Biotechnology (IIT Roorkee, India) PhD in Cell Biology (University of Bern, Switzerland) Research Interests: Pillai’s work centers on RNA biology, particularly the role of RNA modifications (e.g., m6A, m6Am) in development and fertility. He investigates piRNA biogenesis, transposon silencing, and the molecular mechanisms of RNA-protein interactions. His studies bridge biochemistry, genetics, and structural biology to elucidate how RNA molecules regulate critical biological processes. Teaching & Service: At the University of Geneva, he teaches Molecular Biology courses (BSc/MSc levels) and advises 5 PhD students and 4 postdocs. He chairs the ERC Consolidator Grant Review Panel and organizes major conferences like the PIWI/piRNAs Meeting and Swiss RNA Workshop. Pillai also serves on editorial boards for Nucleic Acids Research and RNA . Awards: ERC Consolidator Grant (2015) Best PhD Thesis Award (2003) RNA Society Scaringe Award (2005) Grants & Labs: Funded by ERC Starting and Consolidator Grants, his lab explores RNA modification networks in germ cells. Former trainees include Professors Simon Conn (Flinders University) and Hao Wu (CAS, China).
Xian Wu, Ph.D., serves as a Research Assistant Professor in the Department of Pharmacology & Toxicology at East Carolina University's Brody School of Medicine. Her research leverages human stem cell models to investigate developmental vulnerabilities to environmental contaminants in cardiovascular and neural systems, with emphasis on epigenetic mechanisms and disease modeling. Dr. Wu's academic credentials include: Ph.D. in Toxicology from the University of Georgia M.S. in Biomedicine from East China Normal University B.S. in Biotechnology from Anhui University Her postdoctoral training comprised a Fellowship at the National Institute of Environmental Health Sciences and an ORISE Fellowship at the U.S. Food and Drug Administration. Research focuses on creating human stem cell-derived organoid systems to model developmental toxicology, particularly examining cardiac and neural development under chemical exposure. The laboratory employs fluorescence reporter systems and RNA-seq to identify critical vulnerability windows during early development, with recent work targeting Parkinson's disease mechanisms through dopaminergic neuron models and cardiac fibrosis via advanced organoids. Methodological innovations include high-content imaging for neurogenesis quantification and epigenetic pathway analysis. Publication trends (2016-2025) demonstrate consistent advancement in stem cell-based toxicology testing, with increasing emphasis on micro/nanoplastics risk assessment, arsenic neurotoxicity mechanisms, and doxorubicin cardiotoxicity modeling. The work bridges environmental health, epigenetics, and regenerative medicine through interdisciplinary approaches. Scientific recognition includes: 2025 SPARC Award (ECU) 2024 Top Abstract Award (Developmental Origins of Health and Disease Society) 2024 NIEHS P30 Center Travel Award 2023 ECU Research and Creative Activity Award Dr. Wu actively mentors graduate researchers including Ph.D. candidate Cate Duncan and M.S. students Kamilah Muhammad and Bailey Skeen, alongside undergraduate Bryce Tilghman. Former trainees McKyrah Brown and Monica Cross completed honors theses in the laboratory. Current grants include ECU's SPARC Award funding stem cell model development for environmental contaminant testing. The BSOM 6S-11 laboratory maintains specialized capabilities in cardiac and cerebral organoid generation, fluorescence-based toxicity screening, and RNA-seq epigenetic analysis. Collaborative networks include the National Institute of Environmental Health Sciences and ECU's Center for Human Health and the Environment, supporting translational research on developmental vulnerability periods.
Igor Jurisica is a Professor at the University of Toronto and a Senior Scientist at the Krembil Research Institute’s Data Science Discovery Centre for Chronic Diseases. He also serves as Visiting Scientist at IBM CAS, Scientific Director of the World Community Grid, and Chief Scientist at the Creative Destruction Lab (Rotman School of Management). His research focuses on integrative computational biology, data mining, and AI-driven models for cancer mechanisms, drug discovery, and chronic disease management. Key affiliations include the Osteoarthritis Research Program, Schroeder Arthritis Institute, and leadership roles in open science initiatives like the World Community Grid, a global distributed computing platform with 810,000+ volunteers. Jurisica’s work bridges computational tools (e.g., NAViGaTOR visualization platform, MirDIP databases) and clinical applications, emphasizing explainable AI in healthcare. Research interests span proteomics, microRNA regulation, systems vaccinology, and multi-omics integration for disease stratification. Notable contributions include identifying prognostic signatures in cancer and osteoarthritis, machine learning models for drug repurposing, and sportomics analyses of athletic biomarkers. He has been recognized as a Thomson Reuters Highly Cited Researcher (2014-2016) and ranked among the Top 100 AI Leaders in Oncology (2023). His labs develop open-access tools like PathDIP, OsteoDIP, and miRAnno to advance translational research.
Prof. Dr. Tunç ÇATAL is a Professor of Molecular Biology and Genetics at Üsküdar Üniversitesi. He holds a PhD from İstanbul Technical University (2008) and conducted postdoctoral research at Oregon State University and the National University of Ireland Galway. His expertise spans microbial biotechnology, molecular biology, and hydrogen production. Education: BSc in Biology, İstanbul University (2001) MSc in Biology, İstanbul University (2004) PhD in Molecular Biology-Genetics and Biotechnology, İstanbul Technical University (2008) Administrative Roles: Head of Molecular Biology and Genetics Department (English Program) Director of PROMER Research Center Bologna Coordinator and Erasmus Coordinator His research focuses on microbial electrochemical systems, bioremediation, and bioenergy. Notable contributions include optimizing hydrogen production using microbial electrolysis cells and studying the effects of pharmaceuticals on microbial fuel cell efficiency. He has supervised 3 graduate theses and holds TÜBİTAK awards for impactful publications. His work integrates environmental science and molecular biology, with applications in sustainable energy (e.g., hydrogen production) and wastewater treatment. Recent studies explore novel curcumin compounds for toxicity mitigation and marine mucilage-based bioelectrochemical systems.
Claudio R. Alarcón is an Associate Professor in Pharmacology at Yale University School of Medicine. His research focuses on RNA metabolism's role in development, health, and disease, particularly RNA modifications and non-coding RNAs. He joined Yale in 2017 after postdoctoral training at The Rockefeller University and holds a PhD from Cornell University (2009) and a BSc from Pontificia Universidad Católica de Chile (1999). Research Interests: Functional roles of m6A RNA modifications MicroRNA biogenesis and cancer progression Non-coding RNA regulation in metastasis Key Appointments: Primary Faculty, Yale Cancer Biology Institute Member, Yale Cancer Center Faculty, Yale Combined Program in Biological and Biomedical Sciences His lab integrates bioinformatics, molecular, and cellular approaches to study cancer metastasis mechanisms, including miRNA processing disruptions and SOX4/TMEM2 pathways linked to clinical outcomes.
Jennifer Broderick is a Lecturer at the RNA Therapeutics Institute within UMass Chan Medical School in Worcester, MA. Her academic journey includes a BA from the University of Wisconsin School of Medicine and Public Health, a BS in Molecular Biology from the University of Wisconsin-Madison, and a PhD in Philosophy from the University of Massachusetts Medical School. Her research focuses on RNA therapeutics, microRNA function, and molecular biology mechanisms. Key areas include: RNA interference and silencing pathways MicroRNA quantification and therapeutic applications Gene regulation through splicing mechanisms Protein-RNA interactions in mammalian systems Her publications show consistent focus on RNA biology, with recent work advancing therapeutic RNA design and microRNA quantification techniques. Earlier research explored tau protein splicing and RNA silencing mechanisms. Dr. Broderick collaborates with prominent researchers including Phillip Zamore and Guangping Gao, and is part of the RNA Therapeutics Institute research community.
Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.
Miler T. Lee is an Associate Professor at the University of Pittsburgh , focusing on gene regulation during early embryonic development through high-throughput experimental and computational genomics. He earned his Ph.D. in Genomics and Computational Biology in 2009 from the University of Pennsylvania under Dr. Junhyong Kim, followed by postdoctoral work with Dr. Antonio Giraldez at Yale University. Joining the university in 2016, his research spans maternal-to-zygotic transition (MZT), RNA stability, pluripotency networks, and evolutionary developmental biology, utilizing model organisms like zebrafish, Xenopus, and Hydractinia symbiolongicarpus. Key Research Themes: Maternally inherited RNA dynamics during embryogenesis Mechanisms of RNA degradation and transcriptome remodeling Evolution of pluripotency networks in hybrid species Role of zinc signaling in fertilization barriers Computational tools for RNA regulation and sensing Scientific Awards: Pan-American Society for Evolutionary Developmental Biology Junior Faculty Award (2024) Outstanding New Investigator – International Xenopus Board (2023) Basil O'Connor Scholar – March of Dimes (2017-2019) Recent publications highlight his work on enhancer classification, RNA degradation mechanisms, and cross-species MZT comparisons. His lab develops innovative methods like RESA for regulatory sequence analysis and studies evolutionary divergence in RNA localization patterns. While the articles span computational and experimental approaches, they consistently address RNA's role in cellular identity, developmental timing, and evolutionary adaptation. Applications include understanding pluripotency, designing RNA biosensors, and elucidating fertilization barriers. Prospective Ph.D. students are encouraged to contact him for opportunities in gene regulation, development, evo-devo, and computational genomics.
Alexander Nikitin is a Professor of Pathology at Cornell University's College of Veterinary Medicine, Department of Biomedical Sciences. His research focuses on molecular mechanisms linking tissue homeostasis to cancer development using autochthonous mouse models. Key Affiliation: Cornell University, Ithaca, NY Research Niche: Cancer-prone stem cell niches in female reproductive tract and prostate Research Interests Dr. Nikitin investigates how aberrations in p53/miR-34/MET and Rb networks drive malignant transformation of adult stem cells. His work includes: Identification of ovarian surface epithelium stem cell niche Technology-oriented cross-disciplinary collaborations Characterization of cancer initiation mechanisms in reproductive tissues Article Trends His publications span 2003–2025, emphasizing: Mouse models for epithelial cancers Role of tumor suppressor genes (p53, Rb) in cancer miR-34 family's tumor suppression functions Stem cell niche mapping in reproductive tract cancers Genetic drivers of high-grade serous carcinomas Translational research applications Lab Members Current lab personnel include: Andrea Flesken-Nikitin (Assistant Research Professor) Christopher Ashe (Research Support Specialist) Technicians and student researchers
Professor Sir Peter Barnes is a leading figure in respiratory science at Imperial College London's National Heart and Lung Institute (NHLI) . As Professor of Thoracic Medicine , his work focuses on Asthma, COPD, and cellular senescence in lung disease , with over four decades of contributions to understanding inflammatory pathways and therapeutic innovations. Research Interests Mechanisms of chronic airway inflammation in Asthma and COPD Cellular senescence in lung aging and disease progression MicroRNA transfer via extracellular vesicles in COPD pathogenesis Targeted drug delivery for respiratory conditions Global health implications of lung disease Recent Publications highlight trends in: MicroRNA regulation of senescence and inflammation Extracellular vesicle dynamics in lung disease Biologics and corticosteroid efficacy in respiratory conditions Environmental factors influencing COPD and asthma Scientific Recognition Knighthood (2023) for services to respiratory science Fellow of the Royal Society (FRS) and Academy of Medical Sciences (FMedSci) Collaborative Leadership at NHLI has mentored numerous postdocs and researchers. His work intersects with global initiatives like GOLD (Global Initiative for COPD) , influencing clinical guidelines and public health policy.